Credit Suisse Group AG restated their neutral rating on shares of Johnson & Johnson (NYSE:JNJ) in a research note issued to investors on Monday. Credit Suisse Group AG currently has a $123.00 price objective on the stock.

Analyst Recommendations for Johnson & Johnson (NYSE:JNJ)

Several other equities research analysts have also issued reports on the company. Vetr raised Johnson & Johnson from a hold rating to a buy rating and set a $124.21 price target for the company in a research note on Monday, August 22nd. Barclays PLC reaffirmed an overweight rating and set a $125.00 price target (up previously from $120.00) on shares of Johnson & Johnson in a research note on Sunday, July 10th. Zacks Investment Research raised Johnson & Johnson from a hold rating to a buy rating and set a $139.00 price target for the company in a research note on Friday, August 5th. BTIG Research reaffirmed a neutral rating on shares of Johnson & Johnson in a research note on Wednesday, September 7th. Finally, Jefferies Group lifted their price target on Johnson & Johnson from $109.00 to $113.00 and gave the stock a hold rating in a research note on Thursday, July 14th. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and ten have given a buy rating to the company. Johnson & Johnson presently has an average rating of Hold and an average target price of $119.53.

Shares of Johnson & Johnson (NYSE:JNJ) opened at 118.91 on Monday. The company’s 50-day moving average price is $120.26 and its 200 day moving average price is $116.14. Johnson & Johnson has a 1-year low of $89.90 and a 1-year high of $126.07. The firm has a market cap of $325.32 billion, a PE ratio of 22.16 and a beta of 0.61.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, July 19th. The company reported $1.74 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.68 by $0.06. Johnson & Johnson had a return on equity of 24.70% and a net margin of 20.97%. The company earned $18.50 billion during the quarter, compared to analyst estimates of $17.98 billion. On average, analysts predict that Johnson & Johnson will post $6.69 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd were given a $0.80 dividend. The ex-dividend date of this dividend was Friday, August 19th. This represents a $3.20 annualized dividend and a yield of 2.69%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 60.15%.

In related news, CAO Ronald A. Kapusta sold 2,935 shares of the company’s stock in a transaction that occurred on Friday, July 22nd. The stock was sold at an average price of $125.01, for a total value of $366,904.35. Following the transaction, the chief accounting officer now directly owns 28,660 shares of the company’s stock, valued at approximately $3,582,786.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Dominic J. Caruso sold 41,146 shares of the company’s stock in a transaction that occurred on Tuesday, July 26th. The shares were sold at an average price of $125.01, for a total value of $5,143,661.46. Following the completion of the transaction, the vice president now directly owns 157,819 shares in the company, valued at $19,728,953.19. The disclosure for this sale can be found here. 0.11% of the stock is owned by corporate insiders.

Institutional investors have recently added to or reduced their stakes in the stock. Americafirst Capital Management LLC acquired a new position in Johnson & Johnson during the second quarter valued at about $101,000. Tuttle Tactical Management LLC acquired a new position in Johnson & Johnson during the second quarter valued at about $103,000. Lenox Wealth Management Inc. boosted its position in Johnson & Johnson by 24.3% in the second quarter. Lenox Wealth Management Inc. now owns 972 shares of the company’s stock valued at $118,000 after buying an additional 190 shares during the period. Thomas J. Herzfeld Advisors Inc. boosted its position in Johnson & Johnson by 221.2% in the second quarter. Thomas J. Herzfeld Advisors Inc. now owns 1,002 shares of the company’s stock valued at $122,000 after buying an additional 690 shares during the period. Finally, NCM Capital Management Group Inc. acquired a new position in Johnson & Johnson during the second quarter valued at about $127,000. 65.32% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

5 Day Chart for NYSE:JNJ

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.